HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Their initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Biotechnology

Hillevax

Rob Hershberg

Wendy T.

Yang Wang MD, PhD

Anju Chatterji

Tara Raab

Tomoe Felder

Steven Hauser

Shannon Harris

Shane Maltbie

Ozzie Berger

Holger Koch

Christopher Aakre, PhD

Astrid Borkowski

Paul Bavier

Aditya Kohli

Directors Team

Research and Development

Leadership Team

Accounting and Finance

Quality Assurance and Compliance

Vice Presidents

Clinical Operations

Teams at Hillevax